NEWTON, MA – TripAdvisor today announced it has acquired London-based Tripbod, a travel community that helps connect travelers to local experts and, in doing so, is able to deliver to travelers releva
NEWTON, MA – TripAdvisor today announced it has acquired London-based Tripbod, a travel community that helps connect travelers to local experts and, in doing so, is able to deliver to travelers relevant recommendations direct from a local expert. Tripbod employees will operate out of the TripAdvisor London office.
“The Tripbod team understands the important role a strong community plays in helping travelers plan and have the perfect trip,” said Adam Medros, senior vice president, Global Product, TripAdvisor. “Both companies have a shared vision when it comes to delivering on that promise. We are pleased to welcome Tripbod to TripAdvisor as we work together on future developments.”
Sundyne s HMD Kontro Introduces New Resources to Help Specifiers Understand Magnetic Drive Sealless Pump Technology
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
F Hoffmann-La Roche Ltd: Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Message :
Required fields ENSPRYNG is the first and only treatment approved for both adults and adolescents in the EU with AQP4-IgG seropositive NMOSD ENSPRYNG can be used as a monotherapy or in combination with immunosuppressive therapy to reduce relapses and prevent permanent disability In Phase III studies, ENSPRYNG significantly reduced the number and severity of relapses in people with AQP4-IgG seropositive NMOSD Basel, 28 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved ENSPRYNG(R) (satralizumab) for the treatment of adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD), as a monotherapy or in combination with immunosuppressive therapy (IST). ENSPRYNG is the first and only NMOSD treatment that is administered subcutaneously every four weeks, allowing home-dosing af